Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yinlan Tiaozhi Capsule dose-finding trial in primary hyperlipidemia
ChiCTR1900021326Phase 2Recruiting
- Sponsor
- Capital Medical University
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Yinlan Tiaozhi in familial hyperlipidemia (4 arms), sponsored by Capital Medical University. Primary endpoint: 12-week LDL-C relative change from baseline. Started May 2018; status: recruiting.
02
Drugs
Yinlan Tiaozhi
03
Conditions
familial hyperlipidemia
Beyond the preview
Go deeper on ChiCTR1900021326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021326.